Sanofi - American Depositary Shares (NQ:SNY)

52.14 -0.20 (-0.38%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Price and Volume

Volume	2,194,604
Open	52.11
Bid (Size)	51.62 (300)
Ask (Size)	52.28 (300)
Prev. Close	52.34
Today's Range	52.00 - 52.42
52wk Range	44.62 - 60.12
Shares Outstanding	1,250,690,553
Dividend Yield	4.24%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...

Via TokenRing AI

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Performance

YTD	+8.2%	+8.2%
1 Month	+4.2%	+4.2%
3 Month	+4.6%	+4.6%
6 Month	-0.3%	-0.3%
1 Year	+8.7%	+8.7%

More News

Why Roche Holding Stock Popped Today ↗

November 10, 2025

Via The Motley Fool

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Via Investor's Business Daily

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Via Investor's Business Daily

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

Via TokenRing AI

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

Via TokenRing AI

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

Via TokenRing AI

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗

October 28, 2025

Via Benzinga

UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

October 27, 2025

From Medidata Solutions, Inc.

Via GlobeNewswire

Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations

October 24, 2025

Via MarketMinute

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark ↗

October 24, 2025

Via Benzinga

Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion ↗

October 24, 2025

Via Investor's Business Daily

Earnings Scheduled For October 24, 2025 ↗

October 24, 2025

Via Benzinga

Oil Stocks Rally On Trump's Russia Sanctions: What's Moving Markets Thursday? ↗

October 23, 2025

Via Benzinga

Examining the Future: Sanofi's Earnings Outlook ↗

October 23, 2025

Via Benzinga

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

October 23, 2025

From Medidata Solutions, Inc.

Via GlobeNewswire

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy ↗

October 22, 2025

Via Benzinga

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

Via MarketMinute

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease ↗

October 17, 2025

Via Benzinga

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

Via Benzinga

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗

October 17, 2025

Via Stocktwits

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗

October 14, 2025

Via Benzinga

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗

October 09, 2025

Via Investor's Business Daily

Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study ↗

October 08, 2025

Via Benzinga

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?

Yes, Sanofi - American Depositary Shares is publicly traded.

What exchange does Sanofi - American Depositary Shares trade on?

Sanofi - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Sanofi - American Depositary Shares?

The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market

What is the current price of Sanofi - American Depositary Shares?

The current price of Sanofi - American Depositary Shares is 52.14

When was Sanofi - American Depositary Shares last traded?

The last trade of Sanofi - American Depositary Shares was at 11/14/25 04:00 PM ET

What is the market capitalization of Sanofi - American Depositary Shares?

The market capitalization of Sanofi - American Depositary Shares is 65.21B

How many shares of Sanofi - American Depositary Shares are outstanding?

Sanofi - American Depositary Shares has 65B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.